source
- Daiichi Sankyo to restructure its commercial organization, appointing Ken Keller as chief commercialization officerDaiichi Sankyo announced plans to overhaul its commercial operations, with a split of its commercialization activities slated for April 1, 2027. The company has appointed veteran executive Ken Kel…
- FDA approves Roivant's oral dermatomyositis drug Lisraya (brepocitinib)The U.S. Food and Drug Administration has granted approval to Roivant's drug brepocitinib, which will be sold under the brand name Lisraya. The decision marks the first major regulatory clearance f…